2025Q4| 艾伯维免疫明星表现不一：乌帕替尼强势增长，利生奇珠单抗未达预期

Minhua笔记02-05

2月4日，艾伯维（AbbVie）公布2025年第四季度及全年业绩，营收和盈利均超预期。免疫板块表现不一：Humira超预期贡献大部分增长，Skyrizi强劲增长，Rinvoq略低于预期。公司股价当天下跌约4%，投资者对Humira衰退期公司增长仍依赖该药表示担忧。艾伯维第四季度销售额超出预期约2亿美元，这主要得益于其重磅药物Humira（阿达木单抗）的出色表现，而其后续免疫学药物Rinvoq（...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2609558780?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-05 13:57","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2609558780","market":"us","top_or_hot":-1,"title":"2025Q4| 艾伯维免疫明星表现不一：乌帕替尼强势增长，利生奇珠单抗未达预期","media":"Minhua笔记","content":"<div>\n<p>2月4日，艾伯维（AbbVie）公布2025年第四季度及全年业绩，营收和盈利均超预期。免疫板块表现不一：Humira超预期贡献大部分增长，Skyrizi强劲增长，Rinvoq略低于预期。公司股价当天下跌约4%，投资者对Humira衰退期公司增长仍依赖该药表示担忧。艾伯维第四季度销售额超出预期约2亿美元，这主要得益于其重磅药物Humira（阿达木单抗）的出色表现，而其后续免疫学药物Rinvoq（...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152126a47f0cd8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2025Q4| 艾伯维免疫明星表现不一：乌帕替尼强势增长，利生奇珠单抗未达预期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2025Q4| 艾伯维免疫明星表现不一：乌帕替尼强势增长，利生奇珠单抗未达预期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-05 13:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152126a47f0cd8&s=b><strong>Minhua笔记</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2月4日，艾伯维（AbbVie）公布2025年第四季度及全年业绩，营收和盈利均超预期。免疫板块表现不一：Humira超预期贡献大部分增长，Skyrizi强劲增长，Rinvoq略低于预期。公司股价当天下跌约4%，投资者对Humira衰退期公司增长仍依赖该药表示担忧。艾伯维第四季度销售额超出预期约2亿美元，这主要得益于其重磅药物Humira（阿达木单抗）的出色表现，而其后续免疫学药物Rinvoq（...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152126a47f0cd8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0158827948.USD","symbol_name":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152126a47f0cd8&s=b","article_id":"2609558780","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152126a47f0cd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609558780","pubTimestamp":1770271040,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2月4日，艾伯维公布2025年第四季度及全年业绩，营收和盈利均超预期。公司股价当天下跌约4%，投资者对Humira衰退期公司增长仍依赖该药表示担忧。艾伯维第四季度销售额超出预期约2亿美元，这主要得益于其重磅药物Humira的出色表现，而其后续免疫学药物Rinvoq强势增长，但Skyrizi的业绩则低于预期。Skyrizi 增长 32.5%，达到 50 亿美元，超过预期的 49 亿美元；Rinvoq 增长 29.5%，达到 23.7 亿美元，但略低于预期。其中，Skyrizi和Rinvoq预计分别贡献约215亿美元和101亿美元的收入。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","ABBV":"艾伯维公司","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4566":"资本集团","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999015978.USD":"利安颠覆性创新基金A","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","BK4559":"巴菲特持仓","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD"},"translate_title":"2025Q4 | AbbVie's immune stars have mixed performances: upatinib grows strongly, risen cizumab falls short of expectations","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9},"content_text":"2月4日，艾伯维（AbbVie）公布2025年第四季度及全年业绩，营收和盈利均超预期。免疫板块表现不一：Humira超预期贡献大部分增长，Skyrizi强劲增长，Rinvoq略低于预期。公司股价当天下跌约4%，投资者对Humira衰退期公司增长仍依赖该药表示担忧。艾伯维第四季度销售额超出预期约2亿美元，这主要得益于其重磅药物Humira（阿达木单抗）的出色表现，而其后续免疫学药物Rinvoq（乌帕替尼）强势增长，但Skyrizi（利生奇珠单抗）的业绩则低于预期。CEO Rob Michael在公司财报电话会议上表示：“我们实现了创纪录的净销售额，并超额完成了财务承诺。”这家制药公司公布的季度营收为166亿美元，同比增长10%，高于分析师预期的164亿美元。全年销售额达到612亿美元，同比增长8.6%。尽管业绩超出预期，但 Leerink Partners 分析师 David Risinger 指出，Humira“贡献了绝大部分营收增长”，这可能令投资者感到担忧，并解释了艾伯维股价2月4日下跌约 4% 的原因。免疫学是该公司最大的业务板块，其季度销售额增长 17.7%，达到 86 亿美元。Skyrizi 增长 32.5%，达到 50 亿美元，超过预期的 49 亿美元；Rinvoq 增长 29.5%，达到 23.7 亿美元，但略低于预期。另一方面，Humira 自三年前生物类似药竞争出现以来，销售额持续下滑，本季度营收为 12 亿美元，略高于分析师预期的 10 亿美元，但该药的季度销售额仍同比下降近 26%。首席商务官Jeff Stewart表示，Skyrizi和Rinvoq两款药物预计在2025年将实现约259亿美元的合并销售额，同比增长超过80亿美元，“远超我们最初的预期”。他特别强调了Skyrizi的持续增长势头，指出该药物在美国银屑病生物制剂市场的处方份额已超过45%，并在第四季度加速增长。“我们所有治疗方案的新患者和转换患者的覆盖率均超过55%，是排名第二的竞争对手的四倍，”他补充道。与此同时，神经科学板块也表现强劲，营收增长17.9%至30亿美元。抗精神病药物Vraylar（卡利拉嗪）销售额达10亿美元，增长10.5%；治疗用肉毒杆菌毒素Botox增长13.4%至9.9亿美元。偏头痛治疗药物Ubrelvy（ubrogepant/乌布吉泮）3.39亿美元，增长12%；Qulipta（atogepant/阿托吉泮）销售额2.88亿美元，增长42.6%，也都实现了两位数增长。帕金森病治疗药物Vyalev于2024年底获批上市，其季度营收为1.83亿美元，去年全年营收为4.82亿美元。该公司认为，这种24小时持续皮下输注卡比多巴和左旋多巴前体药物的疗法将在2026年成为重磅炸弹级药物。“该药物在国际市场的接受度非常高，我们预计其在美国的销售额也将大幅增长，因为该药物最近已获得美国医保的全面覆盖。”Stewart表示。本季度肿瘤产品组合的收入为17亿美元，同比下降1.5%，其中Imbruvica（伊布替尼）的收入下降20.8%至6.71亿美元。展望未来，艾伯维预测2026年收入约为670亿美元，同比增长约9.5%，调整后每股收益在14.37美元至14.57美元之间。其中，Skyrizi和Rinvoq预计分别贡献约215亿美元和101亿美元的收入。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609558780","isCrawlerRequest":true}